Pfizer Reports Second-Quarter 2010 Results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has reported financial results for second-quarter 2010. Since the acquisition of Wyeth was completed on October 15, 2009, legacy Wyeth products and operations are reflected in the first two quarters of 2010, but not reflected in the first two quarters of 2009.
Image of new antibiotic in action opens up new opportunities
- Details
- Category: GlaxoSmithKline
Detailed pictures showing how a new type of experimental antibiotic can kill bacteria already resistant to existing treatments.(1) The findings could ultimately help scientists to develop new antibiotics to tackle the bacteria responsible for many hospital and community-acquired infections.
TEMPO study further demonstrates the benefits of Azilect® in early Parkinson's disease patients
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) have announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-label extension.
Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy.
Shire Proposes to Expand Specialist Gastrointestinal Portfolio
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that a Luxembourg incorporated wholly-owned subsidiary of Shire plc will launch a voluntary public takeover offer for all the shares in Movetis NV, the Belgium-based European specialty gastrointestinal (GI) company.
AstraZeneca Second Quarter and Half Year Results 2010
- Details
- Category: AstraZeneca
Revenue in the second quarter increased by 1 percent at CER, but was up 3 percent on an actual basis as a result of the positive impact of exchange rate movements.
Bayer increases sales and earnings in the second quarter
- Details
- Category: Bayer
Sales of the Bayer Group rose by 14.6 percent in the second quarter, to EUR 9,179 million (Q2 2009: EUR 8,009 million). Adjusted for currency and portfolio effects, business grew by 9.2 percent.
More Pharma News ...
- FDA Grants Priority Review to Cladribine Tablets
- Lilly Reports Strong Second-Quarter 2010 Results
- Sanofi-aventis expresses concern over the approval of another version of enoxaparin sodium
- Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox®
- Roche posts good half year results
- Pfizer to Offer Free Public Access to Mental Health Assessment Tools
- Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth